The Medipattern Corporation
TSX VENTURE : MKI

The Medipattern Corporation

February 17, 2011 12:01 ET

Medipattern Receives FDA Clearance For Visualize:Vascular™

Commercial Rollout of 3D Vascular Ultrasound Imaging Product Expected in The First Half of 2011

TORONTO, ONTARIO--(Marketwire - Feb. 17, 2011) -

Attention: Business/Financial Editors

The Medipattern Corporation ("Medipattern") (TSX VENTURE:MKI), a pioneer in the development of medical imaging software solutions that help medical practitioners to better understand lesions and critical anatomy, is pleased to announce it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Visualize:Vascular™ product. Visualize:Vascular is designed to quantify image data; segmenting and measuring regions of interest in vessels. Visualize can help a physician assess vascular disease using ultrasound imaging readily available in most cardiology, vascular radiology and vascular surgery practices today. The product is now available for sale in the United States. First shipments are anticipated in the second quarter of this calendar year.

"Visualize:Vascular allows me to see the structure of the open space in the artery, the residual lumen, which is available for blood flow to the brain. This can be seen in both two and three dimensions which enable us to pinpoint the exact area of critical narrowing in the blood vessel. The beauty of this technology is that it is totally non invasive and can serve as an adjunct to standard duplex ultrasound. Traditionally, we use Doppler to measure the velocities of blood flow in the vessel. From this data we estimate the degree of narrowing to determine if there is significant disease. Visualize affords us the ability to measure the lumen directly. Clinically this is a tremendous asset for us and will ultimately lead to improved patient care," commented Francis J. Porreca, MD, FACS, RPVI, Director of Vascular Surgery, Weiler Division of Montefiore, The University Hospital of the Albert Einstein College of Medicine. "We have had the opportunity to work with Medipattern over the past few years as they developed Visualize. We have an ongoing data base that we are using to track ultrasound and visualize images with the use of Visualize. I believe Visualize has the potential to revolutionize the way we look at ultrasound which will have a positive impact on patient management. We look forward to clinical use where we can document the value of this new and exciting technology."

"Visualize:Vascular brings a whole new look and feel to vascular ultrasound: color 3D reconstruction of specific regions of interest in vessels. Vascular ultrasound is one of the largest and higher growth market segments for ultrasound imaging today. NAVIX specializes in vascular laboratory services. We work closely with vascular labs to increase use of quality standards and protocols," commented Robert Kane, Senior Vice President of Clinical Services, Navix Diagnostix, Inc. "We saw that Medipattern's technology had the power to let us see inside vessels in an ultrasound setting. We became quite enthusiastic about the potential and joined Medipattern in collecting data for them to develop Visualize. Medipattern's imaging algorithm expertise; diligence and dedication have enabled them to bring this product to market. The preliminary response from the physicians that we regularly work with is very enthusiastic and we are committed to seeing this product roll out through our NAVIX sites and expect it to be received well by all vascular labs, cardiology, radiology and surgical practices performing vascular ultrasound."

"Visualize:Vascular is based on the Cadenza™ algorithm platform. To create Visualize, we have both expanded our platform by leveraging it from breast imaging to vascular imaging; and simplified our platform from computer aided detection (CAD) as we do in breast imaging to 3D reconstruction of segmented regions of interest. This allows us to focus on visualization which enables our customers to get a better mental picture of the subject and from this make a detailed analysis," commented Jeff Collins, President and CEO of The Medipattern Corporation. "We wish to thank all of our data collection partners. Their belief in us and direction has been inspirational to us. Visualize:Vascular will be deployed through our data collection sites in a limited roll out followed by sales to key partners and then released for general sales. First shipments are expected next quarter."

About The Medipattern Corporation:

Medipattern® is a pioneer in the development of imaging software solutions that help medical practitioners to better understand lesions and critical anatomy. Our first-to-market, award-winning B-CAD® advances breast ultrasound computer aided detection (CAD) by streamlining workflow and organizing information into a comprehensive patient record. Medipattern uses its Cadenza™ CAD Technology to power the digital conversion in medical communications. B-CAD automatically creates fully digital standardized worksheets and reports that make every practice more efficient, productive and ultimately more effective. For more information, please visit the Company's website at: www.medipattern.com

B-CAD® and Medipattern® are a registered mark of The Medipattern Corporation.

Forward-looking statements

This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential", and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings, (posted at www.sedar.com). In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information